SRRA... following reverse stock split... Gilead Sciences, Inc. (Gilead) will be issued approximately 725,000 shares of common stock (on a post-split basis) and a warrant to purchase an equivalent amount of common stock, in consideration for amending the royalty rates and milestones in an Asset Purchase Agreement with Gilead for momelotinib.

PR: https://finance.yahoo.com/news/sierra-oncolog...00366.html

Gilead is getting into oncology. Can someone please elaborate on what SRRA has and comparison to CYDY.

I understand their product is second in line, for some cancers, and they are expecting Phase 3 data Q4 2021, and still a lot of uncertainties.